Every time your body encounters a bacterium, a first-responder system fires before the adaptive immune response even wakes up. Toll-Like Receptor 2 (TLR2)¹¹ Toll-Like Receptor 2 (TLR2)
TLR2 is a pattern-recognition receptor on the surface of macrophages, monocytes, dendritic cells, and epithelial cells stands at this front line, recognizing bacterial lipoproteins, peptidoglycan, lipoteichoic acid, and mycobacterial components. The R753Q variant (rs5743708), caused by a G-to-A transition at nucleotide 2258, replaces the positively charged arginine with neutral glutamine at position 753 in the receptor's TIR domain²² TIR domain
the Toll/IL-1 receptor domain — the intracellular signaling region that recruits adaptor proteins and initiates the inflammatory cascade. This single amino acid swap disables much of TLR2's capacity to fire.

The R753Q variant is almost exclusively a European polymorphism: approximately 3% of people of European descent carry at least one copy, compared to less than 0.3% in African and East Asian populations. This population specificity makes it a particularly important variant for European-ancestry users.

The Mechanism

The substitution of glutamine for arginine at position 753 changes the electrostatic potential of the DD loop³³ electrostatic potential of the DD loop
a structural element in the TIR domain critical for protein-protein interactions — the precise region where adaptor proteins dock onto TLR2. The consequences cascade through the entire signaling chain: R753Q TLR2 exhibits severely impaired tyrosine phosphorylation⁴⁴ severely impaired tyrosine phosphorylation
4.8-7.5-fold reduction compared to wild-type — a proximal step required for signaling complex assembly, fails to efficiently dimerize with its partner TLR6 (5.9-8-fold reduction), and blocks recruitment of the adaptor proteins MAL and MyD88 that relay the signal to NF-κB.

The end result: where wild-type TLR2 produces 42-fold induction of IL-8 in response to inactivated Mycobacterium tuberculosis components, R753Q TLR2 produces only 4-fold induction⁵⁵ 4-fold induction
even a 100-fold increase in mutant TLR2 expression cannot overcome this deficit. The defect is qualitative, not merely quantitative — the receptor is functionally crippled regardless of how much of it is present. Studies using knock-in mice confirmed that macrophages expressing R753Q show reduced TNF-α, IL-1β, IL-6, and IL-10 production⁶⁶ reduced TNF-α, IL-1β, IL-6, and IL-10 production
along with impaired IRAK-1, p38, ERK1/2, and NF-κB p65 phosphorylation upon mycobacterial challenge.

The Evidence

Tuberculosis is the most extensively studied consequence. A meta-analysis of 19 case-control studies⁷⁷ meta-analysis of 19 case-control studies
4,970 tuberculosis cases and 4,105 controls from Asian and Caucasian populations found that the A allele confers an odds ratio of 2.80 for tuberculosis disease across all genetic models, rising to 5.80 for AA homozygotes. The risk is consistent across both Asian and Caucasian populations, though slightly higher in Asians (OR 3.42 vs 2.39 in Caucasians in the allelic model).

CMV after transplantation shows the most dramatic individual finding. A study of 737 liver transplant recipients⁸⁸ 737 liver transplant recipients
92 patients (12.5%) developed CMV disease within 24 months found that homozygosity for R753Q was associated with a hazard ratio of 3.41 for tissue-invasive CMV disease. This reflects TLR2's documented role in recognizing CMV glycoprotein B — cells expressing R753Q TLR2 show abrogated NF-κB activity when challenged with CMV⁹⁹ abrogated NF-κB activity when challenged with CMV
validating the clinical transplant findings with functional data.

Atopic dermatitis with a severe phenotype clusters in R753Q carriers. The polymorphism defines a distinct subgroup¹⁰¹⁰ defines a distinct subgroup
9 of 78 AD patients (11.5%) were heterozygous for R753Q with median SCORAD scores of 55.8 vs 44.8 in non-carriers, and all carriers had SCORAD above 30 — indicating at least moderate disease. All carriers showed higher total IgE and Dermatophagoides pteronyssinus-specific IgE. A subsequent meta-analysis of nine studies¹¹¹¹ meta-analysis of nine studies
OR 2.07 for atopic dermatitis risk in Caucasians with GA genotype confirmed this association. The mechanism links to impaired IL-8 secretion in response to S. aureus¹²¹² impaired IL-8 secretion in response to S. aureus
which colonizes the skin of nearly all severe AD patients and perpetuates the inflammatory cycle.

Sepsis susceptibility is also elevated. A study using both computational structural modeling and patient data found significant association between TLR2 Arg753Gln and sepsis¹³¹³ significant association between TLR2 Arg753Gln and sepsis
under the over-dominant model, p=0.043, consistent with the expected biology of reduced inflammatory signaling impairing bacterial clearance.

Practical Implications

The picture painted across all these studies is consistent: R753Q carriers mount a blunted initial response when TLR2 ligands are present. This matters most for gram-positive bacteria (which produce the peptidoglycan and lipoproteins TLR2 recognizes), mycobacteria, and certain viruses like CMV. The implications are practical: faster medical attention for infections, optimizing vaccination status, and — for those with atopic dermatitis — recognizing that S. aureus colonization management is especially important.

Lyme disease is a notable exception. Patients with R753Q show significantly lower frequency in severe late-stage Lyme disease¹⁴¹⁴ significantly lower frequency in severe late-stage Lyme disease
possibly due to reduced inflammatory pathology from attenuated TLR2 responses to Borrelia spirochetes, suggesting the dampened immune response can be protective when the disease is primarily driven by immune overactivation rather than pathogen burden.

Interactions

TLR2 does not act alone. It forms heterodimers with TLR1 (recognizing triacylated lipopeptides) and TLR6 (recognizing diacylated lipopeptides and lipoteichoic acid) — and R753Q directly impairs this dimerization. TLR1 rs5743618, a common coding variant, alters TLR1 surface expression and affects combined TLR1/TLR2 signaling; the CGG haplotype (rs5743618–rs5743708–rs5743810 in TLR6) was associated with increased leprosy susceptibility in a Colombian population, suggesting additive effects across the TLR1/2/6 recognition complex.

The CD14 gene (rs2569190)¹⁵¹⁵ CD14 gene (rs2569190)
CD14 encodes the co-receptor that presents bacterial lipopolysaccharide and lipoproteins to TLR2 and TLR4 encodes a co-receptor that delivers bacterial products to TLR2 and TLR4. CD14 variants that reduce its expression would compound TLR2 R753Q impairment, potentially amplifying the signaling deficit further.

For individuals with TLR2 R753Q who also carry TLR4 Asp299Gly (rs4986790), the innate immune system faces a double impairment: blunted gram-positive and mycobacterial recognition (TLR2) alongside reduced gram-negative endotoxin recognition (TLR4). This combined state would warrant heightened infection awareness across a wider pathogen spectrum.

Your liver clears cholesterol from the bloodstream using a receptor called SR-BI, encoded by the SCARB1 gene. SR-BI is the primary docking site where HDL particles offload their cholesterol cargo for processing and excretion in bile — the final step of reverse cholesterol transport¹¹ reverse cholesterol transport
the process by which cholesterol is shuttled from peripheral tissues back to the liver for elimination. When SR-BI expression is reduced, HDL particles circulate longer without fully unloading their cargo, which can impair the liver's ability to process cholesterol and may subtly raise cardiovascular risk.

The rs5888 variant is a synonymous change in exon 8 of SCARB1 — synonymous meaning the amino acid sequence of the protein is unchanged. Yet the variant still matters: not every nucleotide change that preserves an amino acid is functionally neutral.

The Mechanism

Despite producing the same alanine amino acid (Ala350Ala), rs5888 alters the RNA secondary structure of the SCARB1 transcript. The T allele (the A allele on the genomic plus strand) creates a different codon — GCC instead of GCT — that causes the ribosomal machinery to stall. A key in vitro study²² key in vitro study
Constantineau et al. A synonymous variant in scavenger receptor, class B, type I gene is associated with lower SR-BI protein expression and function. Atherosclerosis, 2010 showed that cells expressing the risk variant have significantly lower SR-BI protein levels (p<0.04) and markedly reduced capacity for HDL cholesterol ester uptake (p<0.00001). The transcript levels are identical between genotypes — the difference is purely translational, with more mRNA trapped in non-translating ribosomal pools.

SR-BI also transports dietary carotenoids — particularly lutein and zeaxanthin — to the retinal pigment epithelium, where they form the macular pigment that filters harmful blue light. Impaired SR-BI activity can reduce delivery of these protective pigments to the macula, which may explain the AMD association described below.

The Evidence

A meta-analysis of 12 studies totalling 12,147 subjects³³ meta-analysis of 12 studies totalling 12,147 subjects
Ye et al. Meta-analysis of the association between SCARB1 polymorphism and fasting blood lipid levels. Oncotarget, 2017 found that T-allele carriers (in plus-strand notation: A-allele carriers) had significantly higher HDL-C and lower triglycerides specifically in non-Asian men (SMD 0.15 for HDL-C; p≤0.001). A separate meta-analysis of 7 studies⁴⁴ meta-analysis of 7 studies
Ma et al. SCARB1 rs5888 gene polymorphisms in coronary heart disease: A systematic review and meta-analysis. Gene, 2018 (6,360 subjects) found the T allele associated with reduced coronary heart disease risk in males (OR 0.79; 95% CI 0.61–1.01).

The effects are sex-specific and age-dependent. A Lithuanian population study⁵⁵ A Lithuanian population study
Stanislovaitiene et al. SCARB1 single nucleotide polymorphism (rs5888) is associated with serum lipid profile and myocardial infarction in an age- and gender-dependent manner. Lipids Health Dis, 2013 of 2,439 subjects found that TT homozygous older males (65–74 years) had dramatically reduced MI risk (OR 0.24, 95% CI 0.10–0.56, p=0.001) and higher HDL levels. In young females (25–44 years), TT was associated with lower LDL-C. A smaller Amish cohort⁶⁶ smaller Amish cohort
Roberts et al. Variants in scavenger receptor class B type I gene are associated with HDL cholesterol levels in younger women. Hum Hered, 2007 similarly found rs5888 associated with higher HDL-C in women under 50 but not in older women.

A pharmacogenomics study⁷⁷ pharmacogenomics study
Wu et al. Sex-Specific Influence of the SCARB1 Rs5888 SNP on the Serum Lipid Response to Atorvastatin in Patients with Acute Coronary Syndrome. Pharmgenomics Pers Med, 2020 found that female ACS patients carrying the T allele had a greater reduction in LDL-C and ApoB after atorvastatin treatment, suggesting genotype-specific statin responsiveness in women.

AMD and Carotenoid Transport

A case-control study⁸⁸ case-control study
Zerbib et al. rs5888 variant of SCARB1 gene is a possible susceptibility factor for age-related macular degeneration. PLoS One, 2009 in French and North American cohorts found that heterozygotes (CT genotype, i.e. AG in plus-strand notation) had substantially elevated AMD risk (pooled OR 2.9, 95% CI 1.6–5.3) compared to CC homozygotes — specifically among subjects without CFH or ARMS2 risk variants. The proposed mechanism is impaired SR-BI-mediated delivery of lutein and zeaxanthin to the retinal pigment epithelium.

This AMD association has not been replicated in large GWAS studies, so it should be interpreted as an emerging finding rather than established science.

Practical Actions

For the AA genotype (TT on coding strand), which has the lowest estimated SR-BI expression, the most directly actionable steps are dietary: ensuring adequate intake of preformed lutein and zeaxanthin (since SR-BI mediates their retinal delivery) and monitoring HDL-C as a surrogate for reverse cholesterol transport efficiency. For women on statins, the rs5888 genotype may influence treatment response, warranting closer monitoring.

Interactions

The lipid effects of rs5888 interact with those of CETP (rs708272) and LIPC (rs1532085) — genes that also regulate HDL metabolism. Individuals carrying risk alleles at multiple HDL pathway loci may have compounded HDL impairment beyond what rs5888 predicts alone. APOE (rs429358) interacts through a different mechanism: APOE ε4 impairs LDL clearance, and combined APOE4 + reduced SR-BI function could produce both LDL elevation and HDL impairment, though formal interaction studies are limited.

Your circulating vitamin B12 is not simply a readout of how much B12 you eat — it is actively shaped by the proteins that carry B12 in your blood and determine how quickly it is cleared from circulation. The FUT2 gene encodes alpha-(1,2)-fucosyltransferase 2¹¹ alpha-(1,2)-fucosyltransferase 2
An enzyme that adds fucose sugar residues to glycan chains on cell surfaces and on secreted proteins, creating the H blood group antigen on mucosal surfaces and modifying the glycosylation of carrier proteins like haptocorrin, an enzyme that influences B12 metabolism through a specific post-translational modification of haptocorrin — the protein that binds most of the B12 in your blood. The Gly258Ser variant (rs602662) changes a glycine to a serine at amino acid position 258 of the FUT2 protein. People with the G allele (Gly258) carry a form of FUT2 that more actively fucosylates haptocorrin, leading to lower measured serum B12. People with two A alleles (Ser258) have altered enzyme activity, less fucosylation of haptocorrin, and paradoxically higher circulating B12 measurements. This variant is in strong linkage disequilibrium²² linkage disequilibrium
When two SNPs are inherited together so frequently that knowing one predicts the other — in this case r² = 0.76-0.92 in Europeans with rs601338 (the W143X nonsense mutation that determines classical secretor status), but represents an independent missense change with its own protein-level consequences on enzymatic activity.

The Mechanism

FUT2 fucosylates haptocorrin³³ haptocorrin
Also called transcobalamin I or R-binder — a heavily glycosylated protein synthesized mainly by salivary glands and gastric mucosa that binds B12 in the gut to protect it from acid degradation, then releases it in the small intestine. In the bloodstream, haptocorrin carries approximately 70-80% of total serum B12, adding fucose residues to its complex glycan chains. This fucosylation affects how haptocorrin is recognized and cleared by the liver. The asialoglycoprotein receptor⁴⁴ asialoglycoprotein receptor
A lectin receptor on hepatocytes that preferentially binds and internalizes glycoproteins bearing exposed galactose or N-acetylgalactosamine residues — residues that become exposed when the terminal sialic acid is removed. Fucosylation competes with sialylation on these glycan positions, altering which glycoforms predominate (ASGR) on liver cells is responsible for clearing haptocorrin from the bloodstream. The degree of fucosylation alters the rate of this hepatic clearance. In carriers of the G allele (Gly258, higher FUT2 activity), haptocorrin is more thoroughly fucosylated, shifts toward the TCIII glycoform, and is cleared more efficiently from the blood — resulting in lower measured serum B12. In AA individuals (Ser258, lower FUT2 activity on this residue), haptocorrin retains more sialylation, resists ASGR-mediated clearance, and accumulates to higher levels in the bloodstream. Critically, Velkova et al. 2017⁵⁵ Velkova et al. 2017
Velkova A et al. The FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin, but not holo-transcobalamin, and is associated with haptocorrin glycosylation. Hum Mol Genet, 2017 demonstrated that these FUT2 variants only affect holo-haptocorrin, not holo-transcobalamin⁶⁶ holo-transcobalamin
The approximately 20-30% of blood B12 bound to transcobalamin II — the only form actively taken up by cells via the TCN2 receptor. Only holoTC reflects the B12 available for cellular use; haptocorrin- bound B12 is not accessible to most cells — the biologically active fraction. This is the critical practical implication: standard serum B12 tests measure total B12 (mostly haptocorrin-bound), and GG individuals with lower total B12 may actually have normal cellular B12 availability, while standard tests can give an artificially low result. Conversely, AA individuals with higher total B12 measurements may have perfectly normal cellular B12 availability.

The Evidence

Two independent GWAS studies identified rs602662 as a top hit for plasma vitamin B12. Tanaka et al. 2009⁷⁷ Tanaka et al. 2009
Tanaka T et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet, 2009 analyzed 3,622 participants in three Italian cohorts and found rs602662 to be the single strongest genetic association with vitamin B12 (p = 2.83 x 10^-20). The combined analysis by Hazra et al. 2008⁸⁸ Hazra et al. 2008
Hazra A et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nat Genet, 2008 in 2,717 women identified the FUT2 locus (lead SNP rs492602, in strong LD with rs602662) at p = 5.36 × 10⁻¹⁷, with GG individuals having substantially lower B12 than the AA group. A 2024 study in kidney transplant patients Kotowski et al.⁹⁹ Kotowski et al.
Kotowski M et al. The Importance of the FUT2 rs602662 Polymorphism in the Risk of Cardiovascular Complications in Patients after Kidney Transplantation. Int J Mol Sci, 2024 found that the G allele was present in 65% of hypertensive patients versus 56% of normotensive patients — consistent with the lower B12 leading to higher homocysteine and greater cardiovascular risk. A metabolic study de Luis et al. 2022¹⁰¹⁰ de Luis et al. 2022
de Luis DA et al. Effect of the variant rs602662 of FUT2 gene on anthropometric and metabolic parameters in a Caucasian obese population. Eur Rev Med Pharmacol Sci, 2022 found that AA homozygotes had significantly lower BMI, better lipid profiles, lower fasting glucose, reduced insulin resistance, and a 72% lower metabolic syndrome risk (OR 0.28) compared to GG+GA carriers — an observation that may connect FUT2 biology to wider metabolic regulation.

Practical Implications

The key practical point for GG individuals (and to a lesser extent GA carriers) is awareness: if your standard serum B12 test comes back in the lower-normal range, your result may be influenced by your genotype rather than your dietary intake alone. Requesting a holotranscobalamin¹¹¹¹ holotranscobalamin
Also called "active B12" or holoTC — the B12 fraction bound to transcobalamin II that is available for cellular uptake. Normal range is typically above 35-50 pmol/L test instead of, or alongside, total serum B12 gives a more accurate picture of your functional B12 status. Alternatively, methylmalonic acid (MMA) — which rises specifically when cells lack functional B12 — provides a direct functional readout. For AA individuals, the opposite consideration applies: your total serum B12 may read higher than average, but this primarily reflects haptocorrin-bound B12 in circulation, not improved cellular availability. Standard B12 testing can be misleadingly reassuring if cellular deficiency is a concern.

Interactions

rs602662 is in strong linkage disequilibrium with rs601338 (W143X, the primary European secretor variant) with r² = 0.76-0.92 in Europeans. Together these variants capture FUT2 enzymatic activity from two different positions in the protein — rs601338 causes complete truncation at Trp143, while rs602662 alters activity at Gly258. The associated B12-lowering effects of both variants are mediated through the same haptocorrin glycosylation mechanism, and their effects largely overlap in European populations. For individuals of East Asian ancestry, the classical W143X non-secretor allele (rs601338) is nearly absent. A different FUT2 variant, rs1047781 (A385T, Ile129Phe), is the primary East Asian non-secretor allele. The rs602662 Gly258Ser change is correspondingly rare in East Asian populations, making this variant much less informative in that ancestry context. The downstream effect of lower B12 from GG genotypes intersects with one-carbon metabolism. Vitamin B12 is required for the methionine synthase reaction that converts homocysteine back to methionine. Chronically lower B12 can raise homocysteine, increasing cardiovascular and neurological risk. This interaction is especially relevant in individuals who also carry MTHFR variants (rs1801133 C677T or rs1801131 A1298C) that impair folate-driven remethylation — the two pathways jointly determine homocysteine levels.

Monoamine oxidase A (MAOA) is a mitochondrial enzyme responsible for breaking down neurotransmitters including serotonin, dopamine, norepinephrine, and epinephrine¹¹ serotonin, dopamine, norepinephrine, and epinephrine
These are key chemical messengers that regulate mood, motivation, stress response, and emotional regulation. The rs6323 variant, despite being synonymous (meaning it doesn't change the amino acid sequence at position 297), significantly affects how efficiently this enzyme works. This is a classic example of how ²² DNA changes don't need to alter protein structure to have meaningful biological effects — they can influence gene expression, mRNA stability, or protein folding.

The variant exists in two forms: G, which produces higher MAOA activity, and T, which produces lower activity³³ G, which produces higher MAOA activity, and T, which produces lower activity
The G allele encodes the high-activity form while T encodes the low-activity form. Because MAOA is located on the X chromosome, males (who have only one X) express whichever version they inherit, while females (with two X chromosomes) can have varying combinations. About 29% of Europeans carry the T (lower activity) allele, with higher frequencies in East Asian populations (~48%).

The Mechanism

MAOA requires flavin adenine dinucleotide (FAD) as a covalently attached cofactor⁴⁴ flavin adenine dinucleotide (FAD) as a covalently attached cofactor
FAD is derived from riboflavin (vitamin B2) and is permanently bound to the MAOA enzyme. The R297R variant affects enzyme activity through mechanisms that remain incompletely understood but likely involve mRNA stability or protein folding efficiency rather than direct catalytic changes. Studies show the G allele is associated with 2-10 times higher MAOA expression compared to the T allele⁵⁵ Studies show the G allele is associated with 2-10 times higher MAOA expression compared to the T allele
This translates to faster breakdown of monoamine neurotransmitters.

Lower MAOA activity (T allele) leads to slower breakdown of serotonin, dopamine, and norepinephrine, resulting in higher baseline levels of these neurotransmitters. Conversely, higher activity (G allele) means faster degradation and potentially lower neurotransmitter availability, though the body often compensates through feedback mechanisms and altered receptor sensitivity⁶⁶ feedback mechanisms and altered receptor sensitivity
The relationship between MAOA activity and mood is complex and influenced by environmental factors.

The Evidence

The rs6323 variant has been extensively studied in psychiatric and behavioral contexts. A study of major depressive disorder found that patients with the highest-activity G or GG genotypes had significantly lower placebo response⁷⁷ A study of major depressive disorder found that patients with the highest-activity G or GG genotypes had significantly lower placebo response
PMID: 19593178. This suggests they may be less responsive to psychological interventions alone.

In Korean children, the TT genotype was protective against ADHD in girls with an odds ratio of 0.31⁸⁸ In Korean children, the TT genotype was protective against ADHD in girls with an odds ratio of 0.31
PMID: 29782859. Park et al., 2018. Journal of Korean Medical Science. However, results vary by sex and population, with some studies showing opposite effects in males versus females.

Research on aggression has linked the low-activity variants to increased impulsivity and reactive aggression, particularly in individuals who experienced childhood adversity⁹⁹ Research on aggression has linked the low-activity variants to increased impulsivity and reactive aggression, particularly in individuals who experienced childhood adversity
The gene-environment interaction is crucial — the variant alone doesn't determine behavior. The so-called "warrior gene" association has been sensationalized in media but represents a modest effect size in scientific studies¹⁰¹⁰ "warrior gene" association has been sensationalized in media but represents a modest effect size in scientific studies
The variant contributes to behavioral tendencies but doesn't determine outcomes.

Evidence level is strong based on consistent replication across multiple populations, though effect sizes are generally modest and highly context-dependent.

Practical Implications

For those with lower MAOA activity (T allele carriers), higher baseline neurotransmitter levels can manifest as emotional intensity, stress sensitivity, or difficulty with emotional regulation. Riboflavin is essential for MAOA function as the precursor to FAD¹¹¹¹ Riboflavin is essential for MAOA function as the precursor to FAD
Adequate B2 status supports optimal enzyme activity. Some individuals with slow MAOA variants report benefits from riboflavin supplementation (100-400 mg daily)¹²¹² riboflavin supplementation (100-400 mg daily)
This supports FAD synthesis and may help normalize enzyme activity.

MAOA activity naturally increases with age and in response to oxidative stress¹³¹³ MAOA activity naturally increases with age and in response to oxidative stress
This means someone with genetically low activity might find symptoms moderate over time. Higher activity variants (G allele) may benefit from ensuring adequate precursors for neurotransmitter synthesis.

For treatment response, antidepressant choice may be influenced by MAOA genotype, though this isn't yet standard clinical practice¹⁴¹⁴ antidepressant choice may be influenced by MAOA genotype, though this isn't yet standard clinical practice
SSRIs work by different mechanisms than MAO inhibitors and may have variable effectiveness. MAO inhibitors are typically reserved for treatment-resistant depression.

Interactions

rs6323 interacts with rs1137070, another functional MAOA variant¹⁵¹⁵ rs1137070, another functional MAOA variant
Together these define MAOA haplotypes with different activity levels. The uVNTR (variable number tandem repeat) in the MAOA promoter is perhaps the most well-known MAOA variant and works in combination with rs6323 to determine overall enzyme activity. Compound heterozygosity or multiple low-activity alleles across these variants can result in markedly reduced MAOA activity¹⁶¹⁶ Compound heterozygosity or multiple low-activity alleles across these variants can result in markedly reduced MAOA activity
This may increase susceptibility to mood and behavioral regulation challenges.

MAOA activity also influences the metabolism of tyramine, a dietary amine found in aged cheeses, fermented foods, and red wine¹⁷¹⁷ the metabolism of tyramine, a dietary amine found in aged cheeses, fermented foods, and red wine
Low MAOA activity can increase sensitivity to tyramine and risk of hypertensive reactions when combined with MAO-inhibiting medications.

SH2B1 (SH2B Adaptor Protein 1) is not a hormone or a receptor — it is the adaptor protein¹¹ adaptor protein
Scaffold proteins that assemble multi-protein signaling complexes at specific cellular locations that turns up the volume on two of the body's most important weight-control signals: leptin and insulin. When SH2B1 works properly, it binds to activated JAK2²² JAK2
Janus Kinase 2 — the intracellular enzyme activated when leptin binds its receptor on hypothalamic neurons, dramatically amplifying its catalytic activity and extending downstream signaling through STAT3³³ STAT3
Signal Transducer and Activator of Transcription 3 — the transcription factor that mediates leptin's appetite-suppressing gene expression program and the PI3-kinase pathway. The rs7498665 variant introduces a single amino acid change that appears to blunt this amplification, particularly in leptin signaling.

The GIANT consortium GWAS⁴⁴ GIANT consortium GWAS
Speliotes et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nature Genetics, 2010 identified the SH2B1 locus as one of 18 new genome-wide significant loci for BMI — notable because it sits alongside FTO, MC4R, POMC, and BDNF as one of the few obesity loci that maps directly to a known hypothalamic regulator of energy balance.

The Mechanism

The Thr484Ala substitution falls in the linker region between SH2B1's two key structural domains: the pleckstrin homology (PH) domain⁵⁵ pleckstrin homology (PH) domain
Binds inactive JAK2; positions SH2B1 at the receptor complex before leptin signaling begins (residues 249-378) and the SH2 domain⁶⁶ SH2 domain
Binds phosphorylated, active JAK2; required for full JAK2 activation and downstream signaling (residues 521-625). Position 484 is thus a structural hinge. The ancestral threonine is a polar, hydroxyl-bearing amino acid; the Ala484 substitution removes this polar group, potentially altering how the two domains orient relative to each other and how efficiently SH2B1 transitions from its inactive to active conformation.

Functional evidence confirms the signaling impact is real but leptin-selective. Experiments in hypothalamic cell lines⁷⁷ Experiments in hypothalamic cell lines
Giuranna et al. The Effect of SH2B1 Variants on Expression of Leptin- and Insulin-Induced Pathways in Murine Hypothalamus. Obesity Facts, 2018 showed that SH2B1 variants collectively altered expression of 34 of 54 analyzed leptin signaling genes, with the 484Ala form among the most impactful. Notably, insulin signaling was unaffected, leading the authors to conclude that "leptin rather than insulin signaling is relevant for the mode of action of SH2B1 variants on energy homeostasis." Mice lacking SH2B1 entirely develop severe hyperleptinemia, obesity, and type 2 diabetes — confirming the gene's essential role.

The Evidence

The Thr484Ala variant has been replicated across multiple independent populations. A Belgian case-control study⁸⁸ Belgian case-control study
Beckers et al. Replication of the SH2B1 rs7498665 association with obesity in a Belgian study population. Obesity Facts, 2011 of 1,045 obese adults and 317 lean controls confirmed the G allele increased obesity risk (OR 1.26, 95% CI 1.04-1.52, p=0.016). Japanese CT imaging data revealed the risk allele was significantly associated with visceral fat area⁹⁹ significantly associated with visceral fat area
Hotta et al. SH2B1 rs7498665 and visceral fat area in Japanese adults. Journal of Human Genetics, 2011 (P=0.00047) but not with overall BMI or subcutaneous fat, suggesting a depot-specific effect — the G allele drives abdominal fat accumulation selectively.

Beyond obesity, a study of 18,014 middle-aged Danes¹⁰¹⁰ 18,014 middle-aged Danes
Sandholt et al. Studies of Metabolic Phenotypic Correlates of 15 Obesity Associated Gene Variants. PLOS ONE, 2011 found the G allele independently increased type 2 diabetes risk even after adjusting for BMI (OR 1.16, p=7.8×10⁻⁴). This BMI-independent diabetes association points to a direct metabolic role for SH2B1 beyond its weight-regulatory function — consistent with SH2B1's role in insulin receptor signaling.

Gene-environment interactions are particularly striking. A 2024 study found that GG homozygotes with elevated fasting glucose¹¹¹¹ GG homozygotes with elevated fasting glucose
Chermon et al. Gene-Environment Interactions Significantly Alter the Obesity Risk of SH2B1 rs7498665 Carriers. Journal of Obesity & Metabolic Syndrome, 2024 (≥90 mg/dL) faced 5.82-fold elevated risk of overweight/obesity — while physical activity (≥150 min/week) reduced GG carriers' obesity risk by 65%.

Practical Actions

Because SH2B1 is the amplifier for leptin's satiety signal, strategies that enhance leptin sensitivity are specifically relevant for G allele carriers. High-protein meals trigger satiety hormones (GLP-1, PYY, CCK) via gut receptors that bypass SH2B1-dependent hypothalamic signaling, providing an alternative brake on appetite. The visceral fat–specific association means that measuring waist circumference, not just weight or BMI, gives a more accurate picture of metabolic risk for this genotype.

The fasting glucose interaction is actionable: keeping fasting glucose below 90 mg/dL substantially modifies risk for GG carriers. This threshold is below the standard prediabetes cutoff (100 mg/dL), making periodic fasting glucose testing an important early warning tool.

Interactions

SH2B1 sits directly upstream of the same leptin-JAK2-STAT3 pathway affected by LEPR (rs1137101). Carrying the G risk allele here while also carrying the G risk allele at LEPR rs1137101 compounds impairment at two consecutive steps in leptin signaling: SH2B1 fails to amplify JAK2, and the receptor itself may respond less efficiently to leptin. The cumulative effect on satiety signaling is greater than either variant alone.

rs7498665 also interacts additively with the major obesity GWAS loci FTO (rs9939609) and MC4R (rs17782313) — each variant contributes an independent BMI increment, and carriers of risk alleles at multiple loci face substantially higher cumulative obesity susceptibility. The IRS1 variant rs2943641 affects the insulin receptor substrate arm of SH2B1 signaling; co-occurrence may compound insulin sensitivity effects.

When researchers published the first genome-wide association study to identify IL23R as an inflammatory bowel disease gene in 2006, rs7517847 was the single most significant marker in the entire locus¹¹ single most significant marker in the entire locus
P=3.36×10−13 in the combined analysis of both ileal CD case-control cohorts in Duerr et al. Science 2006 — the landmark study that opened the modern era of IBD genetics. That study found the less common G allele was dramatically less frequent in Crohn's disease patients than in healthy controls (33% vs. 44%), establishing the T allele as the risk variant and the G allele as protective. The variant sits in an intron of IL23R²² IL23R
the gene encoding the IL-23-specific subunit of the heterodimeric IL-23 receptor complex on chromosome 1p31.3, which together with IL12RB1/IL-12Rβ1 forms the complete receptor for the Th17-polarizing cytokine IL-23, the receptor for a cytokine that drives Th17 cell expansion and sustains the inflammatory cascades underlying Crohn's disease, ulcerative colitis, ankylosing spondylitis, and psoriasis.

Crucially, rs7517847 operates in a distinct linkage disequilibrium block³³ linkage disequilibrium block
LD blocks are chromosomal regions where nearby variants tend to be inherited together; low LD between two variants means they are statistically and biologically independent signals from the other shipped IL23R variant, rs2201841 (r²=0.03 between the two). They are independent signals capturing different aspects of IL23R genetic architecture within the same locus.

The Mechanism

IL23R encodes the IL-23-specific receptor subunit that, together with the shared IL-12Rβ1 subunit, forms the complete IL-23 receptor complex. Upon IL-23 binding, the receptor activates JAK2 and TYK2, which phosphorylate STAT3 and STAT4, driving expression of RORγt — the master transcription factor for Th17 cell differentiation. Sustained Th17 expansion underlies the epithelial damage in IBD, joint inflammation in ankylosing spondylitis, and keratinocyte hyperproliferation in psoriasis.

rs7517847 is an intronic variant that does not change the IL-23 receptor protein sequence. Its mechanism is regulatory⁴⁴ regulatory
intronic variants can influence splicing efficiency, mRNA stability, transcription factor binding within intronic enhancers, or alternative isoform ratios — any of which could subtly modulate receptor surface density or signaling output. The G allele is associated with reduced IL-23 pathway activation, parallel in direction (though independent in mechanism) to the well-characterized protective missense variant rs11209026 (R381Q), which directly reduces receptor surface expression. rs7517847 represents a second, distinct molecular entry point to damping the same IL-23/Th17 axis.

The T allele is the ancestral common form (~59% globally) and represents baseline or slightly elevated pathway activity. Homozygous T carriers do not have an overactive receptor — rather, GG carriers appear to have a slightly reduced set point for IL-23 signaling that confers population-level protection against Th17-driven inflammatory diseases, especially in people of European ancestry.

The Evidence

The foundational study by Duerr et al. published in Science in 2006⁵⁵ foundational study by Duerr et al. published in Science in 2006
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene, Science 2006 genotyped 297 individuals with ileal Crohn's disease and 148 controls, then replicated in a second cohort, and found rs7517847 to be the most strongly associated IL23R marker (P=3.36×10−13). The G allele frequency was 0.443 in controls and only 0.331 in CD cases, giving an odds ratio of 0.62 for the protective G allele.

A meta-analysis of 25 studies (9,297 CD cases, 12,643 controls)⁶⁶ meta-analysis of 25 studies (9,297 CD cases, 12,643 controls)
Du et al. Scientific Reports 2015 confirmed robust protection: G allele OR=0.699 (95% CI 0.659–0.741, P<0.001) overall, with the Caucasian-specific effect even stronger (OR=0.669). No significant protective effect was seen in Asian or African populations, making this a Caucasian-predominant signal. A complementary meta-analysis of 11 Caucasian studies⁷⁷ meta-analysis of 11 Caucasian studies
Zhang et al. 2015 framing the T allele as the risk factor found TT vs GG homozygote comparison OR=1.890 (95% CI 1.465–2.437) and dominant model OR=1.652 (95% CI 1.277–2.137) for T risk-allele carriers.

For ankylosing spondylitis, a meta-analysis of 4 studies (1,006 AS cases, 1,190 controls)⁸⁸ ankylosing spondylitis, a meta-analysis of 4 studies (1,006 AS cases, 1,190 controls)
Xu et al. PeerJ 2015 found G allele protective OR=0.88 (95% CI 0.78–0.99, P=0.032) and GG vs TT OR=0.76 (P=0.038). The authors concluded that it was the rs7517847 polymorphism rather than rs2201841 that held the primary statistical association with AS. A separate meta-analysis of 12 UC studies (3,589 cases, 5,536 controls)⁹⁹ meta-analysis of 12 UC studies (3,589 cases, 5,536 controls)
Ye et al. 2017 showed G allele protective OR=0.818 (95% CI 0.768–0.871, P<0.001) in Caucasian populations.

The consistency across CD, UC, and AS — each independently replicated — establishes rs7517847 as one of the best-validated non-HLA susceptibility loci for the cluster of IL-23-driven inflammatory diseases.

Practical Implications

For GG carriers, the genetic data indicate a meaningful reduction in susceptibility to Crohn's disease, ulcerative colitis, and ankylosing spondylitis compared to TT carriers, particularly in people of European ancestry. This is a fortunate genotype from an inflammatory disease perspective — but it does not confer immunity, and other genetic and environmental factors still contribute substantially to disease risk.

For TT carriers — the most common genotype (~35% of Europeans) — the elevated risk is real but modest at the individual level. Most TT carriers will never develop Crohn's disease or AS. However, awareness of symptom patterns that suggest early IBD or spondyloarthritis is valuable, since early diagnosis and treatment dramatically improves long-term outcomes in both conditions. The IL-23/Th17 pathway is directly targeted by multiple approved biologics (ustekinumab, risankizumab, guselkumab for IBD and psoriatic disease; secukinumab, ixekizumab for AS), meaning that if inflammatory disease does develop, effective targeted therapies exist.

Note that this variant's protection is predominantly demonstrated in European populations. People of East Asian or African ancestry should interpret GG genotype with more caution, as the population-stratified meta-analyses showed no significant protective signal in these groups — possibly because the T allele frequency is already very high in some Asian populations, limiting the statistical power to detect differences.

Interactions

rs7517847 and rs2201841 are both intronic IL23R variants associated with overlapping disease spectra but tag independent LD blocks (r²=0.03). Carriers who are TT at rs7517847 (risk) and GG at rs2201841 (risk) face elevated susceptibility from both independent signals — the two variants capture distinct aspects of IL23R regulation within the same gene. Conversely, carrying the protective G allele at rs7517847 alongside the protective A allele at rs2201841 may provide additive dampening of IL-23 pathway activity.

The other major IL23R protective variant, rs11209026 (R381Q/Arg381Gln), acts through a different mechanism — directly reducing receptor surface expression — and is in very low LD with rs7517847 (r²=0.03). The three IL23R signals (rs7517847, rs2201841, rs11209026) each independently tag the same biological pathway through distinct molecular entry points.

For Crohn's disease specifically, documented gene-gene interactions between IL23R variants and NOD2/CARD15 variants (rs2066844, rs2066845) suggest that TT carriers who also carry NOD2 risk alleles face a substantially amplified IBD risk. The rs7517847 × NOD2 interaction has not been quantified directly but is biologically plausible given the established IL23R × NOD2 interaction reported for rs2201841.

Preeclampsia — the sudden onset of high blood pressure and proteinuria after 20 weeks of pregnancy — is one of the leading causes of maternal and fetal mortality worldwide, affecting 2–8% of pregnancies. Although its origins are multifactorial, genetic predisposition to elevated blood pressure plays a measurable role. A variant in PLCE1 (phospholipase C epsilon 1), rs932764, sits at the intersection of two well-established biological processes: renal control of blood pressure and the endothelial dysfunction that characterises early preeclampsia.

The Mechanism

PLCE1 encodes phospholipase C epsilon 1¹¹ phospholipase C epsilon 1
a bifunctional enzyme that hydrolyses phosphatidylinositol-4,5-bisphosphate to generate the second messengers IP3 and diacylglycerol (DAG), and also activates Ras/MAPK signaling via its RasGEF domain. In the kidney, PLCE1 is expressed in podocytes — the specialised epithelial cells that form the filtration slits of the glomerular basement membrane. Loss-of-function mutations in PLCE1 cause nephrotic syndrome type 3 (NPHS3), characterised by proteinuria and progressive renal failure; a hallmark that is biochemically similar to the proteinuria of severe preeclampsia.

The rs932764 intronic variant does not alter the protein sequence but is thought to influence PLCE1 expression levels in renal and vascular tissue. The downstream consequence is subtly altered podocyte integrity and glomerular filtration barrier function²² podocyte integrity and glomerular filtration barrier function
the glomerular filtration barrier determines how much protein leaks into urine; impaired barrier function manifests as proteinuria, a cardinal sign of preeclampsia, with knock-on effects on renal sodium handling and vascular tone. IP3/DAG signalling also activates TRPC6 calcium channels³³ TRPC6 calcium channels
transient receptor potential canonical 6 channels; mediators of Ca²⁺ influx in podocytes and vascular smooth muscle cells, linking PLCE1 activity directly to vascular contractility and blood pressure regulation.

The Evidence

The foundational evidence for rs932764 comes from a landmark 2011 multi-stage GWAS of blood pressure by Ehret et al. (ICBP consortium) in Nature⁴⁴ Ehret et al. (ICBP consortium) in Nature
69,395-person discovery in 29 European-descent cohorts, followed by validation in 133,661 additional individuals; total ≈ 200,000 individuals. The G allele at rs932764 was associated with +0.484 mmHg systolic blood pressure (SBP; P=7.1×10⁻¹⁶) and +0.185 mmHg diastolic blood pressure (DBP; P=8.1×10⁻⁷), with a hypertension association P=9.4×10⁻⁹. Although each copy of the G allele adds less than half a millimetre of mercury on average, this effect integrates across a lifetime of continuous blood pressure exposure and compounds with other variants.

A 2023 genome-wide association meta-analysis by Tyrmi et al. in JAMA Cardiology⁵⁵ Tyrmi et al. in JAMA Cardiology
16,743 women with preeclampsia; cohorts from Finland, Estonia, and the InterPregGen consortium identified the PLCE1 locus as one of seven novel preeclampsia risk loci that overlap with established blood pressure loci. The lead signal near PLCE1 (rs10882398) was associated with preeclampsia/gestational hypertension with OR 1.11 (95% CI 1.08–1.14; P=1.77×10⁻¹³) — a finding the authors interpreted through PLCE1's role in podocyte function and the glomerular filtration barrier. The same study noted that several blood pressure genes show pleiotropic effects on cardiometabolic, endothelial, and placental function, consistent with the clinical overlap between chronic hypertension and preeclampsia.

A regional Russian study by Churnosov et al. (Placenta, 2022)⁶⁶ Churnosov et al. (Placenta, 2022)
452 preeclampsia patients and 498 controls, Caucasian, Central Russia found that rs932764 contributed to the highest proportion of epistatic interaction models (≥50%) among ten hypertension susceptibility SNPs examined in preeclampsia. Follow-up work from the same group (Ivanova et al. 2023, two papers⁷⁷ Ivanova et al. 2023, two papers
n=939 HTN cases/466 controls and n=1,405 sex-stratified hypertension analysis) confirmed rs932764's presence in the top interaction model for hypertension: a four-locus combination with TBX2, AC026703.1, and RGL3 (Wald stat=33.53; p_perm<0.001).

Practical Actions

For individuals carrying one or two G alleles, the clinically meaningful period is the periconceptional and prenatal window. The G allele appears to contribute to a subtle but persistent upward pressure on basal blood pressure that may be unmasked by the haemodynamic demands of pregnancy. Specific monitoring strategies — particularly early blood pressure surveillance and attention to proteinuria screening — are indicated rather than generic lifestyle modifications. For carriers considering pregnancy, discussing the PLCE1 finding with an obstetrician or maternal-fetal medicine specialist before conception may allow earlier surveillance planning.

Dietary approaches with specific mechanistic relevance to the PLCE1/podocyte pathway include maintaining adequate dietary nitrate (leafy green vegetables), which supports endothelial nitric oxide production⁸⁸ endothelial nitric oxide production
a key vasodilatory mechanism often impaired in preeclampsia and limiting sodium intake below 2,300 mg/day, which directly reduces the renal filtration burden on structurally compromised glomeruli.

Interactions

The strongest documented interaction context for rs932764 involves NPR3 rs2609002. NPR3 encodes the natriuretic peptide clearance receptor, and loss-of-function variants accelerate ANP clearance from circulation. ANP (atrial natriuretic peptide) promotes renal sodium excretion, counteracts the renin-angiotensin system, and participates in uterine spiral artery remodelling — a process impaired in early preeclampsia pathogenesis. Individuals carrying both PLCE1 rs932764 GG/AG (glomerular filtration compromise) and NPR3 rs2609002 risk genotypes (reduced ANP clearance counter-signalling) may face compounding susceptibility to gestational hypertension through dual impairment of renal pressure regulation — via the structural podocyte axis (PLCE1) and the natriuretic signalling axis (NPR3). Carriers of both risk variants should be considered for early antenatal blood pressure surveillance and pre-conception counselling.

The IL4R gene¹¹ IL4R gene
Interleukin-4 receptor alpha, located at chromosome 16p12.1 encodes the alpha chain of the interleukin-4 receptor, a critical gatekeeper in the immune system's decision to mount allergic-type (Th2) responses. The Q576R variant (rs1801275) is a single nucleotide change (A>G) that replaces glutamine with arginine at position 576 in the intracellular signaling domain. This is not a subtle tweak — it creates a gain-of-function receptor²² gain-of-function receptor
A gain-of-function mutation increases a protein's activity beyond its normal level, rather than reducing or eliminating it that amplifies downstream immune signaling, pushing the immune system toward allergic and inflammatory responses.

The G allele is remarkably common, carried by about 20% of Europeans and up to 69% of individuals of African descent. Despite being classified as benign by ClinVar (it does not cause a discrete genetic disease), the variant has robust associations with asthma severity, atopic dermatitis, elevated IgE levels, and food allergy risk.

The Mechanism

IL-4Rα forms part of two receptor complexes: the type I receptor³³ type I receptor
IL-4Rα paired with the common gamma chain (γc), used primarily by immune cells (with γc) and the type II receptor (with IL-13Rα1). When IL-4 or IL-13 binds, intracellular JAK kinases phosphorylate the receptor, normally activating STAT6 to drive Th2 differentiation, IgE class switching, and mucus production.

The R576 substitution introduces a critical structural change. The arginine at position 576 renders the adjacent tyrosine at Y575 into a consensus binding site for the adaptor protein GRB2⁴⁴ GRB2
Growth factor receptor-bound protein 2, an adaptor that links receptor tyrosine kinases to downstream signaling cascades. When Y575 is phosphorylated by JAKs, GRB2 docks onto the receptor and activates the ERK1/2 MAP kinase cascade⁵⁵ ERK1/2 MAP kinase cascade
Extracellular signal-regulated kinases, part of the mitogen-activated protein kinase pathway that regulates cell growth and differentiation. This drives autocrine IL-6 production, which in turn activates STAT3 — a transcription factor not normally engaged by the wild-type receptor. The result is dual STAT6 and STAT3 activation, promoting a mixed Th2/Th17 inflammatory profile associated with more severe allergic disease and steroid-resistant airway inflammation⁶⁶ steroid-resistant airway inflammation
Inflammation that does not respond adequately to corticosteroid treatment, a hallmark of severe asthma.

Critically, the R576 variant also destabilizes regulatory T cells (Tregs). Induced Tregs expressing R576 show decreased methylation at the Foxp3 CNS2 locus⁷⁷ Induced Tregs expressing R576 show decreased methylation at the Foxp3 CNS2 locus
This epigenetic change makes Tregs unstable and prone to converting into pro-inflammatory Th17 cells, causing them to lose their suppressive function and acquire a Th17-like phenotype. This Treg-to-Th17 conversion further amplifies the inflammatory response.

The Evidence

Clinical evidence for Q576R spans asthma, atopic dermatitis, and food allergy.

A meta-analysis of 7 studies (912 cases, 708 controls)⁸⁸ meta-analysis of 7 studies (912 cases, 708 controls)
All studies from Chinese pediatric populations using PCR-RFLP methodology found the G allele significantly increases pediatric asthma risk across all genetic models: GG versus AA showed OR 3.75 (95% CI 1.89-7.45), AG versus AA showed OR 2.15 (95% CI 1.36-3.39), and the dominant model yielded OR 2.25 (95% CI 1.42-3.57). In a Saudi Arabian population study⁹⁹ Saudi Arabian population study
190 asthmatic and 194 controls, the G allele conferred OR 2.12 (95% CI 1.39-3.22) for asthma susceptibility.

For atopic dermatitis, the evidence emphasizes disease severity rather than susceptibility. In the ADRN cohort of 1,116 Caucasian AD patients¹⁰¹⁰ ADRN cohort of 1,116 Caucasian AD patients
Atopic Dermatitis Research Network, a large prospective cohort, R576 carriers had significantly higher Rajka-Langeland severity scores (p=0.02-0.037). A Vietnamese population study of 113 AD patients and 213 controls¹¹¹¹ Vietnamese population study of 113 AD patients and 213 controls found the G allele associated with higher SCORAD severity scores in the dominant model (OR 4.67, p=0.005), with a clear dose-response: median SCORAD scores of 30.5 (AA), 39 (AG), and 49.65 (GG).

Mouse models confirm the gain-of-function mechanism: IL4raR576 mice showed robust lung eosinophilia with neutrophilia¹²¹² IL4raR576 mice showed robust lung eosinophilia with neutrophilia
Indicating mixed Th2/Th17 inflammation not seen with the wild-type receptor, exaggerated airway hyperresponsiveness, elevated OVA-specific IgE/IgG1, and increased IL-13 secretion by splenocytes compared to wild-type controls.

The variant also mediates food allergy risk through atopic dermatitis. Each risk allele increases odds of AD 1.39-fold, and AD increases odds of food allergy 2.68-fold for severe food allergy symptoms¹³¹³ Each risk allele increases odds of AD 1.39-fold, and AD increases odds of food allergy 2.68-fold for severe food allergy symptoms
Supporting the dual-allergen hypothesis that epicutaneous sensitization through damaged skin barrier drives food allergy, demonstrating that Q576R contributes to the atopic march from eczema to food allergy.

Practical Actions

The core challenge for G allele carriers is an immune system biased toward Th2/allergic responses, with impaired Treg function and a tendency toward steroid-resistant inflammation. Interventions should target this specific imbalance.

Quercetin directly counteracts the IL-4/STAT6 axis. In vitro studies show quercetin at concentrations of 5 micromolar or higher suppresses IL-4-induced STAT6 phosphorylation and Th2 cytokine production¹⁴¹⁴ In vitro studies show quercetin at concentrations of 5 micromolar or higher suppresses IL-4-induced STAT6 phosphorylation and Th2 cytokine production
Peak plasma levels after 1,200 mg oral dose reach approximately 12 micromolar, exceeding the effective in vitro threshold, suppressing IL-5 and IL-13 while restoring IFN-gamma production.

Vitamin D modulates the Th1/Th2 axis. Supplementation with vitamin D3 normalizes Th1 and Th2 interleukin patterns and reduces atopic dermatitis severity¹⁵¹⁵ Supplementation with vitamin D3 normalizes Th1 and Th2 interleukin patterns and reduces atopic dermatitis severity
1,000 IU daily for 3 months significantly reduced SCORAD scores in children with AD, directly relevant to the Th2 polarization driven by this variant.

Total serum IgE measurement quantifies the downstream consequence of enhanced IL-4R signaling and tracks whether interventions are working. Specific IgE panels identify the allergens most affected by your amplified Th2 response.

Interactions

The Q576R variant interacts with two other IL4R polymorphisms: [I75V (rs1805010) | Ile75Val, located in the extracellular domain, also associated with atopy and IgE regulation] and S503P (rs1805015). These three variants form haplotypes with compounded effects on IL-4 signaling. Multiple risk alleles across these loci may additively increase atopic disease susceptibility.

Given IL-4Rα's role in both type I (IL-4) and type II (IL-4/IL-13) receptor complexes, this variant interacts functionally with IL-13 pathway variants. The combined effect of enhanced IL-4R signaling with variations in IL-13 itself could substantially amplify Th2-driven inflammation beyond what either variant produces alone.

The Q576R variant is particularly relevant to dupilumab pharmacology. Dupilumab, a monoclonal antibody blocking IL-4Rα, directly targets the receptor this variant modifies. Carriers of the gain-of-function R576 allele may represent a population with particularly enhanced IL-4R signaling who could benefit most from this targeted blockade, though pharmacogenomic studies specifically linking Q576R genotype to dupilumab response are still emerging.

Methionine synthase reductase (MTRR) is a critical support enzyme in the methylation cycle. Its job is to reactivate methionine synthase (MTR) after it becomes oxidized and inactive during normal operation. Think of MTRR as the maintenance crew that keeps the methylation assembly line running.

The Mechanism

MTR uses methylcobalamin ¹¹ Methylcobalamin: the methyl-carrying form of vitamin B12, one of two bioactive cobalamin forms (active B12) as a cofactor to convert homocysteine to methionine. During this reaction, B12 occasionally becomes oxidized to an inactive form. MTRR steps in to reduce (reactivate) the B12, restoring MTR function. The A66G variant (rs1801394) causes an isoleucine-to-methionine substitution ²² Isoleucine-to-methionine substitution at position 22 of the protein (p.Ile22Met) at position 22, which reduces MTRR's ability to perform this reactivation efficiently. ClinVar classifies this as benign given its very high population frequency, though functional studies show reduced enzyme affinity for MTR.

The Evidence

The GG genotype has been associated with elevated homocysteine³³ associated with elevated homocysteine
Gueant-Rodriguez RM et al. MTRR and neural tube defect risk, 2003 levels in several studies, though the effect is typically smaller than that of MTHFR C677T. A meta-analysis⁴⁴ meta-analysis
Botto LD & Yang Q. Meta-analysis of one-carbon metabolism variants and NTD risk, 2006 found that the G allele modestly increases the risk of neural tube defects and is associated with altered DNA methylation patterns. The variant is extremely common — about 50% of Europeans are heterozygous (AG) and 25% are homozygous (GG).

B12 Form Matters

Because MTRR affects B12 reactivation, the form of B12 you consume may matter. Hydroxocobalamin is the preferred form because it can be readily converted to both methylcobalamin (for methylation) and adenosylcobalamin ⁵⁵ Adenosylcobalamin is the mitochondrial form of B12, essential for energy metabolism via the citric acid cycle (for energy metabolism). Cyanocobalamin (the cheapest supplement form) requires additional conversion steps and may be less efficient if your MTRR is compromised.

Practical Implications

If you carry the G allele, ensuring adequate B12 intake becomes more important than average. This is especially relevant for vegetarians and vegans who may already be at risk for B12 deficiency. Active B12 forms (hydroxocobalamin, methylcobalamin, adenosylcobalamin) may be preferable to cyanocobalamin.

Interactions

MTRR works in concert with MTR (rs1805087) — both variants affect B12 handling in the methylation cycle. Combined with MTHFR variants (rs1801133), impairment at multiple points compounds the effect on overall methylation capacity.

One of the most consistently replicated loci in the genetics of human cognition sits on chromosome 6q16.1. The rs1906252 variant is located within a large uncharacterised non-coding RNA at chr6:98,102,413 (GRCh38), approximately 730 kilobases upstream of POU3F2¹¹ POU3F2
POU class 3 homeobox 2, also known as BRN2 — a transcription factor expressed almost exclusively in the brain that controls the differentiation of upper-layer cortical projection neurons. The gap in linear distance is not unusual for regulatory biology: enhancers and regulatory elements routinely act across hundreds of kilobases via chromatin looping, and the 6q16.1 region harbours several candidate regulatory elements including the brain-expressed microRNA MIR2113²² MIR2113
microRNA 2113, located ~78 kb from rs1906252, which may modulate POU3F2 expression post-transcriptionally.

POU3F2 (BRN2) is essential for the development of cortical layer II–IV projection neurons — the neurons that underlie associative, executive, and higher-order cognitive functions. Mouse knockout experiments demonstrate that loss of POU3F2 produces severe cortical architectural defects, loss of upper-layer neurons, and impaired cognition in memory and learning tasks. The observation that common genetic variation at this locus predicts cognitive performance in humans suggests that the A allele fine-tunes POU3F2 expression during development in a way that produces marginally more efficient cortical organisation.

This SNP is related to rs9320913, another POU3F2 6q16.1 locus variant (~34 kb away) that was the original lead SNP at this locus from the Rietveld 2013 Science educational attainment GWAS. rs1906252 and rs9320913 likely tag overlapping functional elements in this regulatory region.

The Mechanism

The A allele at rs1906252 is the minor allele globally (gnomAD v4: ~39%), though it approaches 50% in European populations (~49%), suggesting drift or mild positive selection in that ancestry group. Each copy of the A allele is associated with a small linear increase in general cognitive ability (g) — the direction is consistent across the allele dose series CC → AC → AA.

The molecular mechanism is not resolved. The variant sits within a 1.2-megabase lncRNA with no characterised function, in a region containing MIR2113. Functional genomics data from adult brain tissue show active regulatory chromatin in this region, consistent with an enhancer role, but no published reporter assay has directly tested the allelic effect of rs1906252 on POU3F2 or MIR2113 expression. The causal variant at this locus may be rs1906252 itself or a nearby variant in strong LD.

The Evidence

Trampush et al. 2015³³ Trampush et al. 2015
American Journal of Medical Genetics B moved this locus beyond genome-wide significance for direct cognitive ability — not merely educational attainment proxy phenotype — by combining the COGENT cognitive GWAS cohort with educational attainment summary statistics in 68,159 individuals, yielding P = 1.65×10⁻⁹ for g. Crucially, the direction was unambiguous: each A allele linearly increased g scores.

Davies et al. 2016⁴⁴ Davies et al. 2016
Molecular Psychiatry confirmed the region in UK Biobank (N = 112,151), identifying 6q16.1 among 20 genome-wide significant regions for cognitive function. Lee et al. 2018⁵⁵ Lee et al. 2018
Nature Genetics — the largest educational attainment GWAS to date, N = 1.1 million — included 1,271 genome-wide significant loci, with pathway analysis pointing to brain-expressed genes in neurodevelopmental pathways.

Hashizume et al. 2018⁶⁶ Hashizume et al. 2018
Genes Brain Behav provided the functional bridge: POU3F2 knockout mice exhibit impaired object recognition, spatial memory, and reduced adult hippocampal neurogenesis, establishing POU3F2 as a critical regulator of memory and learning in the postnatal brain — making it biologically plausible that variation in POU3F2 regulatory elements shapes cognitive differences in humans.

The effect size per A allele is approximately 0.03–0.05 standard deviations in g — small in individual terms but highly significant at population scale. AA homozygotes are not measurably smarter than CC homozygotes in everyday functioning; the signal emerges only in adequately powered population studies.

Practical Actions

For AC and AA carriers, no intervention changes the genotype — the benefit is already present. The practical value is understanding that this locus reflects POU3F2-dependent cortical circuitry, which requires adequate neurotrophic and nutritional support to fully express its potential. Choline is the rate-limiting precursor for cortical acetylcholine neurotransmitter synthesis and phosphatidylcholine membrane production; DHA is the primary structural omega-3 in cortical neuron membranes. Ensuring adequate supply of both specifically supports the POU3F2-specified upper-layer cortical neurons that this locus implicates.

For CC carriers, no pharmacological intervention modifies this variant, but the absence of the A allele simply means this particular locus contributes less to cognitive reserve. The same nutritional considerations apply — arguably more so, since CC individuals have less genetic headroom from this particular pathway.

Interactions

rs1906252 at 6q16.1 and rs9320913 at the same locus likely tag overlapping regulatory elements upstream of POU3F2; individuals with risk alleles at both may have a compounded reduction in POU3F2 pathway tone, but this has not been formally studied. At the pathway level, POU3F2-dependent cortical neurons are the downstream targets of BDNF signalling (rs6265, Val66Met) and dopaminergic modulation (COMT rs4680); individuals carrying risk alleles at those SNPs alongside CC at rs1906252 would have compounded reductions in cortical circuit efficiency, though no published study has modelled the combined genetic effect.